Advertisement
News
Advertisement

No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa® (dabigatran etexilate) compared to enoxaparin for VTE pre...

Mon, 06/25/2012 - 4:24am
Boehringer Ingelheim

Ingelheim, Germany, 25 June 2012 – Findings from an analysis of four Phase III trials, comparing Pradaxa® to enoxaparin recently published in Thrombosis Research, support the positive safety profile of Pradaxa® for the prevention of venous thromboembolism (VTE) in patients undergoing total knee or hip arthroplasty. The results demonstrate that the risk of acute coronary syndrome (ACS) events was low and that there was no significant difference in between the two treatments. The analysis concluded that Pradaxa® does not elevate the risk of myocardial infarction (MI) compared to enoxaparin and is not associated with any clinically important 'rebound effect' in the post-treatment period. 1

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading